Asset Acquisition, Contingent Value Right, Right To Receive Contingent Payments

No definition available.

Name:	avtx_AssetAcquisitionContingentValueRightRightToReceiveContingentPayments
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Asset Acquisition Number Of Contingent Consideration Milestones

+ References

No definition available.

+ Details

Name:	avtx_AssetAcquisitionNumberOfContingentConsiderationMilestones
Namespace Prefix:	avtx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative Arrangement, Rights and Obligations, Cumulative Milestone Payment Expense Recognized to Date

+ References

No definition available.

+ Details

Name:	avtx_CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments

+ References

No definition available.

+ Details

Name:	avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights and Obligations, Patent Costs

+ References

No definition available.

+ Details

Name:	avtx_CollaborativeArrangementRightsAndObligationsPatentCosts
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights and Obligations, Percent of Payments From Sublicensing

+ References

No definition available.

+ Details

Name:	avtx_CollaborativeArrangementRightsAndObligationsPercentOfPaymentsFromSublicensing
Namespace Prefix:	avtx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Collaborative Arrangement, Rights and Obligations, Upfront Fee

+ References

No definition available.

+ Details

Name:	avtx_CollaborativeArrangementRightsAndObligationsUpfrontFee
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Contract With Customer, Revenue Recognized to Date From Milestone Payments

+ References

No definition available.

+ Details

Name:	avtx_ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

License Agreement, Make Whole Payment Per Unit

+ References

No definition available.

+ Details

Name:	avtx_LicenseAgreementMakeWholePaymentPerUnit
Namespace Prefix:	avtx_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Preclinical Therapies

+ References

No definition available.

+ Details

Name:	avtx_NumberOfPreclinicalTherapies
Namespace Prefix:	avtx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Payment For Asset Acquisition Contingent Consideration Liability Operating Activities

+ References

No definition available.

+ Details

Name:	avtx_PaymentForAssetAcquisitionContingentConsiderationLiabilityOperatingActivities
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue, Remaining Performance Obligation, Variable Consideration Amount

+ References

No definition available.

+ Details

Name:	avtx_RevenueRemainingPerformanceObligationVariableConsiderationAmount
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Royalty Agreement, Buyout Option, Percentage Of Net Present Value Of Royalty Payments

+ References

No definition available.

+ Details

Name:	avtx_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments
Namespace Prefix:	avtx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty Agreement, Payment Received

+ References

No definition available.

+ Details

Name:	avtx_RoyaltyAgreementPaymentReceived
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Royalty Agreement, Period After Public Launch To Terminate Agreement

+ References

No definition available.

+ Details

Name:	avtx_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement
Namespace Prefix:	avtx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of liability recognized from contingent consideration in asset acquisition.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 50
-Section 15
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492

+ Details

Name:	us-gaap_AssetAcquisitionContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

+ Details

Name:	us-gaap_GeneralAndAdministrativeExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of units of goods that must be purchased within the specified time period of the agreement to avoid penalties or unfavorable effects on pricing, among other adverse consequences.

+ References

No definition available.

+ Details

Name:	us-gaap_LongTermPurchaseCommitmentMinimumQuantityRequired
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_OperatingLeasedAssetsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 912
-SubTopic 730
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	dei_LegalEntityAxis=avtx_AeviGenomicMedicineIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=avtx_AeviGenomicMedicineIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=avtx_IchorionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	avtx_MilestoneAxis=avtx_MilestoneOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	avtx_MilestoneAxis=avtx_MilestoneTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	avtx_MilestoneAxis=avtx_MilestoneThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=avtx_CERC801CERC802AndCERC803Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=avtx_CERC913Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=avtx_TRISPharmaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=avtx_KarbinalAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=avtx_KyowaKirinCoLtdKKCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=avtx_AVTX002KKCLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=avtx_AstellasPharmaIncAstellasMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=avtx_AVTX006AstellasLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=avtx_AstraZenecaPlcAstraZenecaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=avtx_AVTX007AstraZenecaLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=avtx_SanfordBurnhamPrebysMedicalDiscoveryInstituteMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=avtx_AVTX008SanfordBurnhamPrebysLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=avtx_AltoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=avtx_AVTX301OutLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=avtx_ESMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=avtx_AVTX406LicenseAssignmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=avtx_AVTX611LicenseAssignmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=avtx_JanssenPharmaceuticalsIncJanssenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=avtx_AVTX501Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies (Details) $ / shares in Units, $ in Thousands			1 Months Ended		3 Months Ended	12 Months Ended
	Feb. 03, 2020 USD ($) milestone	Sep. 24, 2018 USD ($) milestone therapy	Jul. 31, 2019 USD ($)	Aug. 31, 2017 USD ($)	Mar. 31, 2020 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2018 unit $ / shares	Jun. 22, 2021 USD ($)	Jun. 09, 2021 USD ($)	May 28, 2021 USD ($)	Mar. 25, 2021 USD ($)	Aug. 31, 2019 USD ($)
Operating Leased Assets [Line Items]
General and administrative						$ 21,832	$ 17,418
Proceeds from sale						5,398	6,699
Royalty agreement, payment received			$ 2,000
Period after public launch to terminate agreement			3 years
Buyout option, percentage of net present value of royalty payments			75.00%
Aevi
Operating Leased Assets [Line Items]
Payment for contingent consideration						0
Aevi
Operating Leased Assets [Line Items]
Number of contingent consideration milestones \| milestone	2
Contingent consideration	$ 6,500				$ 6,500
Ichorion
Operating Leased Assets [Line Items]
Number of contingent consideration milestones \| milestone		3
Contingent consideration		$ 15,000
Payment for contingent consideration						0
Milestone One \| Aevi
Operating Leased Assets [Line Items]
Contingent consideration	2,000
Milestone One \| Ichorion
Operating Leased Assets [Line Items]
Payment for contingent consideration		6,000
Milestone Two \| Aevi
Operating Leased Assets [Line Items]
Contingent consideration	$ 4,500
Milestone Two \| Ichorion
Operating Leased Assets [Line Items]
Payment for contingent consideration		5,000
Milestone Three \| Ichorion
Operating Leased Assets [Line Items]
Payment for contingent consideration		$ 4,000				0
License revenue
Operating Leased Assets [Line Items]
Proceeds from sale				$ 25,000		625	$ 0
CERC-801, CERC-802, And CERC-803 \| Ichorion
Operating Leased Assets [Line Items]
Number of preclinical therapies \| therapy		3
CERC-913 \| Ichorion
Operating Leased Assets [Line Items]
Number of preclinical therapies \| therapy		1
TRIS Pharma \| Karbinal Agreement
Operating Leased Assets [Line Items]
Minimum quantity required \| unit								70,000
Make whole payment per unit (in dollars per share) \| $ / shares								$ 30
Kyowa Kirin Co., Ltd. (KKC) \| AVTX-002 KKC License Agreement
Operating Leased Assets [Line Items]
Upfront license fee												$ 10,000
Percent of payments received from sublicensing												30.00%
Research and development						10,000
Kyowa Kirin Co., Ltd. (KKC) \| AVTX-002 KKC License Agreement \| Milestone One
Operating Leased Assets [Line Items]
Maximum aggregate milestone payment												$ 112,500
Kyowa Kirin Co., Ltd. (KKC) \| AVTX-002 KKC License Agreement \| Milestone Two
Operating Leased Assets [Line Items]
Maximum aggregate milestone payment												$ 75,000
Astellas Pharma, Inc. (Astellas) \| AVTX-006 Astellas License Agreement
Operating Leased Assets [Line Items]
Upfront license fee						500
Maximum aggregate milestone payment						5,500
Research and development						500
Cumulative expense recognized to date						500
AstraZeneca plc (AstraZeneca) \| AVTX-007 AstraZeneca License Agreement
Operating Leased Assets [Line Items]
Upfront license fee						6,000
Research and development						0
Cumulative expense recognized to date						1,500
AstraZeneca plc (AstraZeneca) \| AVTX-007 AstraZeneca License Agreement \| Milestone One
Operating Leased Assets [Line Items]
Maximum aggregate milestone payment						71,500
AstraZeneca plc (AstraZeneca) \| AVTX-007 AstraZeneca License Agreement \| Milestone Two
Operating Leased Assets [Line Items]
Maximum aggregate milestone payment						90,000
Sanford Burnham Prebys Medical Discovery Institute \| AVTX-008 Sanford Burnham Prebys License Agreement
Operating Leased Assets [Line Items]
Upfront license fee									$ 400
Research and development						400
Cumulative expense recognized to date						0
Patent costs									500
General and administrative						500
Sanford Burnham Prebys Medical Discovery Institute \| AVTX-008 Sanford Burnham Prebys License Agreement \| Milestone One
Operating Leased Assets [Line Items]
Maximum aggregate milestone payment									24,200
Sanford Burnham Prebys Medical Discovery Institute \| AVTX-008 Sanford Burnham Prebys License Agreement \| Milestone Two
Operating Leased Assets [Line Items]
Maximum aggregate milestone payment									$ 50,000
Alto \| AVTX-301 Out-License
Operating Leased Assets [Line Items]
Maximum proceeds from milestones											$ 18,600
Revenue recognized from milestones to date						0
ES \| AVTX-406 License Assignment
Operating Leased Assets [Line Items]
Revenue recognized from milestones to date						0
ES \| AVTX-406 License Assignment \| Milestone One
Operating Leased Assets [Line Items]
Maximum proceeds from milestones										$ 6,000
ES \| AVTX-406 License Assignment \| Milestone Two
Operating Leased Assets [Line Items]
Maximum proceeds from milestones										$ 20,000
ES \| AVTX-611 License Assignment
Operating Leased Assets [Line Items]
Maximum proceeds from milestones													$ 20,000
Janssen Pharmaceuticals, Inc. (Janssen) \| AVTX-501
Operating Leased Assets [Line Items]
Maximum proceeds from milestones				$ 20,000
Revenue recognized from milestones to date						$ 0